
M J Gooderham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1881143/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 2287-2303.	6.3	884
2	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. New England Journal of Medicine, 2017, 376, 1551-1560.	13.9	413
3	Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderateâ€toâ€severe plaque psoriasis over 52Âweeks: a phase III, randomized controlled trial (ESTEEM 2). British Journal of Dermatology, 2015, 173, 1387-1399.	1.4	384
4	Topical tofacitinib for atopic dermatitis: a phase <scp>II</scp> a randomized trial. British Journal of Dermatology, 2016, 175, 902-911.	1.4	356
5	Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. New England Journal of Medicine, 2018, 379, 1313-1321.	13.9	301
6	Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis. JAMA Dermatology, 2020, 156, 863.	2.0	247
7	Dupilumab: A review of its use in the treatment of atopic dermatitis. Journal of the American Academy of Dermatology, 2018, 78, S28-S36.	0.6	218
8	Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11Âyears old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology, 2020, 83, 1282-1293.	0.6	214
9	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet, The, 2019, 394, 576-586.	6.3	198
10	Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis. JAMA Dermatology, 2019, 155, 1371.	2.0	174
11	Bimekizumab versus Secukinumab in Plaque Psoriasis. New England Journal of Medicine, 2021, 385, 142-152.	13.9	173
12	The efficacy and safety of apremilast, etanercept and placebo in patients with moderateâ€toâ€severe plaque psoriasis: 52â€week results from a phase IIIb, randomized, placeboâ€controlled trial (LIBERATE). Journal of the European Academy of Dermatology and Venereology, 2017, 31, 507-517.	1.3	156
13	Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). Journal of the American Academy of Dermatology, 2016, 74, 134-142.	0.6	138
14	An update on generalized pustular psoriasis. Expert Review of Clinical Immunology, 2019, 15, 907-919.	1.3	122
15	Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis. JAMA Dermatology, 2020, 156, 649.	2.0	120
16	A headâ€toâ€head comparison of ixekizumab vs. guselkumab in patients with moderateâ€toâ€severe plaque psoriasis: 12â€week efficacy, safety and speed of response from a randomized, doubleâ€blinded trial. British Journal of Dermatology, 2020, 182, 1348-1358.	1.4	117
17	Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108Âweeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). Journal of the American Academy of Dermatology, 2017, 77, 855-862.	0.6	104
18	Shifting the focus – the primary role of <scp>IL</scp> â€23 in psoriasis and other inflammatory disorders. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1111-1119.	1.3	80

#	Article	IF	CITATIONS
19	Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of the American Academy of Dermatology, 2018, 78, 70-80.	0.6	78
20	The psychosocial impact of hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2015, 73, S19-S22.	0.6	73
21	Trial of Roflumilast Cream for Chronic Plaque Psoriasis. New England Journal of Medicine, 2020, 383, 229-239.	13.9	71
22	A headâ€ŧoâ€head comparison of ixekizumab vs. guselkumab in patients with moderateâ€ŧoâ€severe plaque psoriasis: 24â€week efficacy and safety results from a randomized, doubleâ€blinded trial*. British Journal of Dermatology, 2021, 184, 1047-1058.	1.4	58
23	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. British Journal of Dermatology, 2018, 179, 615-622.	1.4	57
24	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. Dermatology and Therapy, 2020, 10, 133-150.	1.4	51
25	Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. BioDrugs, 2015, 29, 327-339.	2.2	50
26	Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). British Journal of Dermatology, 2018, 178, 1315-1323.	1.4	44
27	The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature. Journal of Cutaneous Medicine and Surgery, 2019, 23, 298-306.	0.6	43
28	Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. Drugs in Context, 2020, 9, 1-9.	1.0	43
29	Review of Systemic Treatment Options for Adult Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2017, 21, 31-39.	0.6	42
30	Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis. Core Evidence, 2018, Volume 13, 13-20.	4.7	41
31	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatology and Therapy, 2020, 10, 431-447.	1.4	40
32	Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document. Journal of Cutaneous Medicine and Surgery, 2017, 21, 513-524.	0.6	39
33	A Review of Psoriasis, Therapies, and Suicide. Journal of Cutaneous Medicine and Surgery, 2016, 20, 293-303.	0.6	37
34	Long-term topical management of psoriasis: the road ahead. Journal of Dermatological Treatment, 2022, 33, 111-120.	1.1	37
35	Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17Âyears of age. British Journal of Dermatology, 2014, 171, 1470-1477.	1.4	32
36	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy, 2022, 12, 495-510.	1.4	30

#	Article	IF	CITATIONS
37	Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab. Journal of Cutaneous Medicine and Surgery, 2020, 24, 588-595.	0.6	29
38	2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. Journal of Cutaneous Medicine and Surgery, 2016, 20, 375-431.	0.6	28
39	Psoriasis Prevalence and Severity by Expert Elicitation. Dermatology and Therapy, 2021, 11, 1053-1064.	1.4	28
40	Phase I randomized study of <scp>KHK</scp> 4083, an antiâ€ <scp>OX</scp> 40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1324-1332.	1.3	23
41	TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors. International Journal of Dermatology, 2022, 61, 139-147.	0.5	23
42	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. Journal of Rheumatology, 2019, 46, 751-754.	1.0	22
43	Abrocitinib for the treatment of atopic dermatitis. Expert Review of Clinical Immunology, 2020, 16, 955-962.	1.3	21
44	Phosphodiesterase-4 Inhibition in Psoriasis. Psoriasis: Targets and Therapy, 2021, Volume 11, 21-29.	1.2	21
45	Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology, 2022, 86, 77-85.	0.6	21
46	Diagnosis of Generalized Pustular Psoriasis. American Journal of Clinical Dermatology, 2022, 23, 31-38.	3.3	21
47	Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. British Journal of Dermatology, 2020, 182, 1359-1368.	1.4	20
48	A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. Journal of Cutaneous Medicine and Surgery, 2018, 22, 78-83.	0.6	17
49	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2018, 22, 21S-29S.	0.6	17
50	Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. Journal of Cutaneous Medicine and Surgery, 2020, 24, 3S-14S.	0.6	16
51	Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis. Annals of Allergy, Asthma and Immunology, 2021, 126, 576-583.e4.	0.5	16
52	The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature. Journal of Cutaneous Medicine and Surgery, 2019, 23, 289-297.	0.6	15
53	Safety of Janus kinase (JAK) inhibitors in the shortâ€ŧerm treatment of atopic dermatitis. International Journal of Dermatology, 2022, 61, 746-754.	0.5	15
54	Realâ€world effectiveness of adalimumab in patients with moderateâ€ŧoâ€severe hidradenitis suppurativa: the 1â€year SOLACE study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2431-2439.	1.3	13

#	Article	IF	CITATIONS
55	Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study. Journal of Drugs in Dermatology, 2020, 19, 734-740.	0.4	13
56	Management of scalp psoriasis: current perspectives. Psoriasis: Targets and Therapy, 2016, 6, 33.	1.2	12
57	The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review. Journal of Cutaneous Medicine and Surgery, 2019, 23, 428-435.	0.6	12
58	Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of interleukin 23. JAAD Case Reports, 2021, 7, 60-61.	0.4	12
59	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology, 2022, 158, 561.	2.0	12
60	Realâ€world, longâ€ŧerm treatment patterns of commonly used biologics in Canadian patients with moderateâ€ŧoâ€severe chronic plaque psoriasis. Journal of Dermatology, 2022, 49, 95-105.	0.6	11
61	Longâ€term, durable, absolute Psoriasis Area and Severity Index and healthâ€related quality of life improvements with risankizumab treatment: a <i>post hoc</i> integrated analysis of patients with moderateâ€toâ€severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. 2022. 36. 855-865.	1.3	11
62	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2018, 22, 30S-35S.	0.6	9
63	Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis. Dermatology and Therapy, 2022, 12, 727-740.	1.4	9
64	Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2019, 23, 5S-10S.	0.6	8
65	Uncommon Adverse Effects of Deoxycholic Acid Injection for Submental Fullness: Beyond the Clinical Trials. Journal of Cutaneous Medicine and Surgery, 2020, 24, 619-624.	0.6	7
66	Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review. Dermatologic Therapy, 2021, 34, e15104.	0.8	7
67	Improvement of granulomatous skin conditions with tofacitinib in three patients: A case report. SAGE Open Medical Case Reports, 2021, 9, 2050313X2110394.	0.2	7
68	Incidence and prognosis of COVIDâ€19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	7
69	Brodalumab: A Review of Safety. Skin Therapy Letter, 2018, 23, 1-3.	0.3	7
70	Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: <i>post hoc</i> analysis of 5â€year data from <scp>reSURFACE</scp> 1 and <scp>reSURFACE</scp> 2. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1774-1783.	1.3	7
71	Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 797-806.	1.3	6
72	Quality of life and patientâ€perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixedâ€dose combination Cal/BD foam: A <i>postâ€hoc</i> analysis of PSO‣ONG. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 60-67.	1.3	6

#	Article	IF	CITATIONS
73	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Journal of Cutaneous Medicine and Surgery, 2018, 22, 3S-5S.	0.6	5
74	Incidence of serious gastrointestinal events among tildrakizumabâ€ŧreated patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e350-e352.	1.3	5
75	Realâ€world experience of dupilumab in the treatment of moderateâ€ŧoâ€severe atopic dermatitis. International Journal of Dermatology, 2020, 59, e361-e363.	0.5	5
76	Realâ€world experience with risankizumab in patients with plaque psoriasis: a retrospective study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e685-e688.	1.3	5
77	Apremilast in the treatment of psoriasis and psoriatic arthritis. Skin Therapy Letter, 2015, 20, 1-6.	0.3	5
78	Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report. SAGE Open Medical Case Reports, 2019, 7, 2050313X1982962.	0.2	4
79	Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. Expert Opinion on Investigational Drugs, 2020, 29, 911-917.	1.9	4
80	Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. Journal of Dermatological Treatment, 2021, 32, 484-491.	1.1	4
81	A case report of recalcitrant aphthous ulcers in two patients treated with interleukin-17 inhibitors. SAGE Open Medical Case Reports, 2021, 9, 2050313X2110349.	0.2	4
82	TYK2 inhibition: changing the treatment landscape for psoriasis?. Expert Review of Clinical Immunology, 2021, , 1-3.	1.3	4
83	High threshold efficacy responses in moderateâ€toâ€severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1308-1317.	1.3	4
84	Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study. Journal of Cutaneous Medicine and Surgery, 2019, 23, 282-288.	0.6	3
85	Topical PDE-4 Inhibitors are Emerging for Psoriasis Treatment. Journal of Cutaneous Medicine and Surgery, 2021, 25, 109-110.	0.6	3
86	Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland. Journal of Dermatological Treatment, 2021, , 1-19.	1.1	3
87	Lymantria dispar dispar (Gypsy) Moth Dermatitis. Journal of Cutaneous Medicine and Surgery, 2021, 25, 555-556.	0.6	3
88	Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a realâ€world setting. British Journal of Dermatology, 2022, 186, 726-728.	1.4	3
89	Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study. Journal of Dermatological Treatment, 2022, 33, 2692-2694.	1.1	3
90	An indirect comparison of longâ€ŧerm efficacy of everyâ€2â€week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's GlobalÂAssessment > 1 at week 12. British Journal of Dermatology, 2020, 183, 52-59.	1.4	2

#	Article	IF	CITATIONS
91	Treatment of Palmoplantar Pustulosis with the Combination of Ustekinumab and Apremilast: A Case Report. Archives of Case Reports in Clinical Medicine, 2016, 02, .	0.0	2
92	Return of <i>Lymantria dispar dispar</i> (gypsy moth): A case report. SAGE Open Medical Case Reports, 2021, 9, 2050313X2110579.	0.2	2
93	Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology. Dermatology and Therapy, 2022, 12, 253-265.	1.4	2
94	Predictors of Topical Use in Psoriasis Patients in the REFINE Study. Journal of Cutaneous Medicine and Surgery, 2016, 20, 106-112.	0.6	1
95	The effectiveness of intralesional <i>Candida</i> antigen immunotherapy as a treatment for anogenital warts: a retrospective chart review. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	1
96	Reverse koebnerization of primary cutaneous follicle center lymphoma following skin biopsy. JAAD Case Reports, 2021, 16, 149-151.	0.4	1
97	Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab. Journal of Cutaneous Medicine and Surgery, 2022, , 120347542210885.	0.6	1
98	Healthcare Providers Face Numerous Challenges in Treating Patients with Psoriasis: Results from a Mixed-Methods Study. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 35-43.	0.3	1
99	Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and Therapy, 2022, 12, 1073-1089.	1.4	1
100	Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot. Blockchain in Healthcare Today, 0, , .	3.4	0
101	Visual Dermatology: Achenbach Syndrome (Paroxysmal Finger Hematoma). Journal of Cutaneous Medicine and Surgery, 2022, , 120347542110733.	0.6	0
102	Alitretinoin: An Update of Real-World Evidence in The Management of Chronic Hand Dermatitis. Skin Therapy Letter, 2018, 23, 1-4.	0.3	0
103	Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 117-121.	0.3	0
104	Practice Patterns Around the Management of Atopic Dermatitis in 2018 and 2020. Journal of Cutaneous Medicine and Surgery, 2022, , 120347542210996.	0.6	0